Trials / Recruiting
RecruitingNCT04804553
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD)
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 5 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apremilast | Participants will receive apremilast orally. |
| DRUG | Placebo | Participants will receive the matching placebo orally. |
Timeline
- Start date
- 2022-03-17
- Primary completion
- 2028-03-21
- Completion
- 2028-12-29
- First posted
- 2021-03-18
- Last updated
- 2026-02-05
Locations
45 sites across 15 countries: Austria, Belgium, France, Germany, Greece, Italy, Lithuania, Netherlands, Poland, Portugal, Romania, South Africa, Spain, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04804553. Inclusion in this directory is not an endorsement.